

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**AIM Vaccine Co., Ltd.**

**艾美疫苗股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 06660)**

**VOLUNTARY ANNOUNCEMENT**  
**PRE-APPLICATION FOR CLINICAL TRIALS FOR HAEMOPHILUS**  
**INFLUENZAE TYPE B CONJUGATE VACCINE SUBMITTED**

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company of the latest business developments of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Group has submitted the pre-application for clinical trials for haemophilus influenzae type b (Hib) conjugate vaccine on March 27, 2024, and the pre-application for clinical trials for absorbed tetanus vaccine on February 9, 2024. The research and development of these two vaccines is in line with the Company’s strategic layout in product research and development, is an important step to realize the Company’s research and development of multidisease and multivalent products, and will further improve the Company’s product pipelines.

Invasive diseases caused by Hib may affect various organs. Common invasive diseases include meningitis, pneumonia, epiglottitis, sepsis, arthritis and cellulitis, and less frequent types of diseases include osteomyelitis, pericarditis, otitis media and acute bronchitis. In addition, the Group is actively promoting the research and development of diphtheria, tetanus and acellular pertussis and haemophilus influenzae type b (DTP-Hib) combination vaccine (hereinafter referred as the “**Multidisease Vaccine**”), and expects to successively submit clinical trial applications for the Multidisease Vaccine and its component vaccines since 2024. The Multidisease Vaccine is used to prevent invasive infections caused by pertussis, diphtheria, tetanus and haemophilus influenzae type b, and has the advantages such as reducing the number of vaccinations for infants and young children and enhancing the vaccination compliance of parents, infants and young children. The Multidisease Vaccine is the development trend of the industry, which provides strong support for the strengthening of the Company’s core competitiveness, enhancement of the Company’s market position, and the Company’s sustainable and steady development.

By order of the Board  
**AIM Vaccine Co., Ltd.**  
**Mr. Yan ZHOU**

*Chairman of the Board, Executive Director  
and Chief Executive Officer*

Hong Kong, March 28, 2024

*As at the date of this announcement, the Board of the Company comprises Mr. Yan ZHOU, Mr. Wen GUAN and Mr. Shaojun JIA as executive directors; Mr. Jie ZHOU, Mr. Xin ZHOU, Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Ms. Jie WEN and Mr. Hui OUYANG as independent non-executive directors.*